Harbrecht U, Bastians B, Kredteck A, Hanfland P, Klockgether T, Pohl C
Institute for Experimental Haematology and Transfusion Medicine, Rheinische Friedrich Wilhelms Universität, Bonn, Germany.
Neurology. 2004 Feb 24;62(4):657-9. doi: 10.1212/01.wnl.0000110187.16764.9a.
The risk for immune-mediated heparin-induced thrombocytopenia (HIT) in neurologic patients receiving unfractionated heparin (UFH) is not known. In a prospective study of 200 patients, the authors found a 2.5% rate of HIT and a 2% rate of HIT-associated thromboses, suggesting that neurologic patients treated with UFH are at considerable risk for development of HIT and its complications. Prevalence of heparin-induced antibodies was 20.5% and was dependent on heparin dose. It was higher in cerebrovascular than in noncerebrovascular (29.4% versus 11.2%, p < 0.01) patients.
接受普通肝素（UFH）治疗的神经系统疾病患者发生免疫介导的肝素诱导的血小板减少症（HIT）的风险尚不清楚。在一项对200名患者的前瞻性研究中，作者发现HIT发生率为2.5%，HIT相关血栓形成率为2%，这表明接受UFH治疗的神经系统疾病患者发生HIT及其并发症的风险相当高。肝素诱导抗体的患病率为20.5%，且取决于肝素剂量。脑血管疾病患者中的患病率高于非脑血管疾病患者（29.4%对11.2%，p<0.01）。
